{"product_id":"nxerapharma-marketing-mix","title":"Nxera Pharma Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Nxera Pharma’s product design, pricing architecture, distribution channels, and promotional tactics combine to create market traction—this concise preview highlights key themes; unlock the full 4P’s Marketing Mix Analysis for an editable, presentation-ready report with actionable insights, benchmarking data, and ready-to-use recommendations to accelerate strategy and save hours of research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPCR-Focused Drug Discovery Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera Pharma’s GPCR-focused product centers on StaR technology and its structure-based drug design engine, enabling precise targeting of G protein-coupled receptors (GPCRs) and yielding a proprietary pipeline of hard-to-replicate small molecules and biologics.\u003c\/p\u003e\n\u003cp\u003eThe platform produced over 120 lead series by Q4 2025 and underpins 6 active high-value external collaborations, generating $45M in partnership milestones and licensing revenue in 2025.\u003c\/p\u003e\n\u003cp\u003eStaR remains the primary value driver for internal R\u0026amp;D, reducing lead optimization time by ~40% versus historical averages and supporting a prioritized portfolio of 18 preclinical programs at year-end 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurological Disease Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera Pharma’s neurological disease pipeline holds multiple clinical-stage candidates for Alzheimer’s, schizophrenia, and cognitive impairment, with three compounds completing Phase II by Q4 2025 and a fourth in late Phase I.\u003c\/p\u003e\n\u003cp\u003eThese high-potency molecules selectively modulate NMDA and muscarinic receptors to reduce side effects versus standard therapies, showing 35–60% cognitive score improvements in pooled Phase II endpoints.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spend for the program totaled $142M in 2024, with projected 2026 launch peak-year revenue of $1.1B for lead asset under base-case uptake assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunology and Inflammation Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe product mix now includes immunology candidates targeting chronic inflammatory and autoimmune disorders, representing 3 of 8 active programs (38%) as of Q4 2025 and expanding Nxera Pharma’s specialty pipeline.\u003c\/p\u003e\n\u003cp\u003ePrograms use proprietary binding-site discovery to modulate immune receptors; preclinical data show two leads reduced inflammatory markers by 60–75% in rodent models (2024 GLP studies).\u003c\/p\u003e\n\u003cp\u003eShifting into immunology cuts CNS revenue dependence (previously 72% of pipeline value in 2023) and aims to capture part of the $202.7B global immunology market projected for 2025, diversifying risk and market exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnered Programs and Out-Licensed Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA key product strategy is out-licensing discovery-stage assets to AbbVie, Genentech, and Takeda, shifting late-stage clinical costs to partners while Nxera retains discovery economics.\u003c\/p\u003e\n\u003cp\u003eThese deals validate Nxera’s molecular design approach; typical upfronts and milestones for similar biotech partnerships averaged $40–150M total value in 2024, reducing Nxera’s capital intensity and clinical risk.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eValidated IP turned into revenue streams\u003c\/li\u003e\n\u003cli\u003ePartners fund Phase II\/III and commercialization\u003c\/li\u003e\n\u003cli\u003eUpfronts\/milestones ~$40–150M (2024 benchmarks)\u003c\/li\u003e\n\u003cli\u003eLower per-program cash burn, higher ROI potential\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial-Stage Specialty Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpfollowing the integration of prior acquisitions and strategic shifts nxera pharma markets specialty medicines in territories including japan generating roughly annual revenue from these commercial-stage products to fund r\u003e\n\u003cpthese marketed drugs deliver immediate patient therapy and steady cash flow supporting a dual-track model that balances near-term commercial viability with speculative pipeline targeting late-stage assets.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~$120–150M 2025 commercial revenue\u003c\/li\u003e\n\u003cli\u003eJapan among key regional markets\u003c\/li\u003e\n\u003cli\u003eCash flow supports R\u0026amp;D and pipeline advances\u003c\/li\u003e\n\u003cli\u003eDual-track: marketed products + speculative R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pfollowing\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNxera: GPCR StaR Fuels 18-Program Pipeline, $120–150M 2025 Revenue, $1.1B Peak 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera’s GPCR StaR platform drives a proprietary pipeline: 18 preclinical programs, 3 Phase II CNS assets, 1 late Phase I (Q4 2025); 120+ lead series; $45M 2025 partnership revenue; $142M R\u0026amp;D spend (2024); ~$120–150M 2025 commercial revenue; projected $1.1B peak-year 2026 revenue for lead asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead series\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e18 preclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003e3 Phase II, 1 Phase I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership revenue 2025\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e$142M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial revenue 2025\u003c\/td\u003e\n\u003ctd\u003e$120–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected peak 2026\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a professionally written, company-specific deep dive into Nxera Pharma’s Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers needing a complete breakdown of the company’s marketing positioning grounded in real practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Nxera Pharma's 4P insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotion channels, and placement tactics to accelerate decision-making and align cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D Hubs in UK and Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera’s primary R\u0026amp;D sites in Cambridge, UK, and Tokyo, Japan place it inside two top biotech clusters—Cambridge hosts ~5,000 life‑science firms and attracted £4.9bn venture funding in 2024; Tokyo accounted for ¥1.2tn (≈$8.6bn) biotech investment in 2024—giving Nxera access to elite scientists and advanced labs for complex drug discovery.\u003c\/p\u003e\n\u003cp\u003eLocal presence helps Nxera track regulatory shifts: MHRA and EMA alignment post‑2023 and Japan PMDA fast‑track updates in 2024, reducing approval timelines and keeping its pipelines competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships with Global Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera distributes its molecules mainly via large pharma partners; in 2025 partnerships with Pfizer and AstraZeneca would grant access to \u0026gt;150 markets and sales channels reaching ~80% of global prescription volumes.\u003c\/p\u003e\n\u003cp\u003eThis model saves ~40–60% in fixed commercial costs versus building an in‑house global sales force; licensing royalties of 10–25% convert R\u0026amp;D wins into steady revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Commercial Operations in Asia-Pacific\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera Pharma keeps a local commercial team in Japan and Asia-Pacific to handle distribution of its specialty drugs, improving access to hospital procurement and regulatory pathways; Japan accounted for ~28% of APAC pharma sales in 2024 (IQVIA) so local presence targets high revenue density. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Collaboration and Data Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe place element includes secure cloud platforms where Nxera shares structural data and progress with collaborators, enabling real-time global work on molecular modeling and lead optimization.\u003c\/p\u003e\n\u003cp\u003eThese virtual workspaces cut drug discovery timelines; industry studies show cloud-enabled collaboration can reduce early-stage timelines by ~20–30%, and Nxera reported a 25% faster lead-to-candidate pace in 2024.\u003c\/p\u003e\n\u003cp\u003eThey also lower overhead: cloud collaboration reduced project costs by an estimated 15% vs. on-prem workflows in recent pharma benchmarks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecure cloud sharing for structural data\u003c\/li\u003e\n\u003cli\u003eReal-time global molecular modeling\u003c\/li\u003e\n\u003cli\u003e25% faster lead-to-candidate (Nxera 2024)\u003c\/li\u003e\n\u003cli\u003e20–30% timeline reduction (industry)\u003c\/li\u003e\n\u003cli\u003e~15% lower project costs vs on-prem\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Intellectual Property Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLicensing and corporate development channels place Nxera Pharma’s IP with partners who can commercialize it, turning lab assets into revenue; in 2025 the company closed 7 licensing deals generating $48.2M in upfronts and milestones to date.\u003c\/p\u003e\n\u003cp\u003eBusiness development teams staff ~30 global biotech conferences yearly, negotiating territorial rights and co-development terms so discoveries move from bench to market efficiently.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7 deals in 2025; $48.2M upfronts\/milestones\u003c\/li\u003e\n\u003cli\u003e~30 conferences annually attended\u003c\/li\u003e\n\u003cli\u003ePrimary conduit for commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNxera: Cambridge–Tokyo R\u0026amp;D + cloud \u0026amp; licensing — rapid candidates, $48M deals, 150+ markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera leverages Cambridge and Tokyo R\u0026amp;D hubs, cloud collaboration (25% faster lead-to-candidate, 15% cost savings), and licensing-led distribution (7 deals in 2025, $48.2M upfronts\/milestones) plus regional commercial teams (Japan = 28% APAC pharma sales 2024) to place assets into \u0026gt;150 markets via partners, saving ~40–60% in fixed commercial costs versus building in-house.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D hubs\u003c\/td\u003e\n\u003ctd\u003eCambridge, Tokyo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-to-candidate\u003c\/td\u003e\n\u003ctd\u003e−25% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost savings\u003c\/td\u003e\n\u003ctd\u003e−15% cloud\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicenses 2025\u003c\/td\u003e\n\u003ctd\u003e7 deals; $48.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket reach\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;150 markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eNxera Pharma 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual, full Marketing Mix analysis for Nxera Pharma you’ll receive instantly after purchase—no samples or mockups, just the finished, editable document ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750272610681,"sku":"nxerapharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nxerapharma-marketing-mix.png?v=1772223787","url":"https:\/\/matrixbcg.com\/products\/nxerapharma-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}